What question did this study set out to answer?

This study aims to evaluate the clinical outcomes of neoadjuvant pembrolizumab plus chemotherapy in patients with triple-negative breast cancer.

May 24, 2026Open Access

334eP Retrospective and prospective analysis of microinvasive breast cancer: Clinicopathological features, treatment and outcomes-A single institutional experience

Key Points

This study aims to evaluate the clinical outcomes of neoadjuvant pembrolizumab plus chemotherapy in patients with triple-negative breast cancer.
Retrospective analysis using electronic medical records from patients with Stage II-III triple-negative breast cancer.
Evaluation of characteristics, clinical outcomes, and treatment responses from August 2021 to July 2022.
Descriptive summary of pathologic complete response and event-free survival outcomes.
61.4% of patients achieved pathologic complete response (pCR).
Estimated 3-year median event-free survival (rwEFS) was 89.8% for patients achieving pCR compared to 71.2% for those not achieving pCR.
13 events were observed among the included patients during the follow-up period.

Abstract

Background: Neoadjuvant pembrolizumab (pembro) plus chemotherapy was approved in July 2021 for high-risk, early-stage triple-negative breast cancer (TNBC) based on improved event-free survival in the KEYNOTE-522 trial.Real-world evidence describing clinical outcomes following pembro use in patients with TNBC in routine practice remains limited. Methods:This retrospective real-world study used electronic medical records accessed via the N-power Medicine platform to evaluate adults with Stage II-III TNBC who initiated neoadjuvant pembro plus chemotherapy between August 2021 and July 2022.Patient characteristics and clinical outcomes, including pathologic complete response (pCR) and 3-year event-free survival endpoints, were summarized descriptively. Results: In total, 88 patients with Stage II (54.5%) or Stage III (45.5%)TNBC received neoadjuvant pembro plus chemotherapy.At diagnosis, 39.8% were aged 50 years, 34.1% were 51-64 years, and 26.1% were 65 years.AH1 AV2 Most patients were White (61.4%), and nearly all received carboplatin as part of neoadjuvant therapy (97. 7%).MM3 AH4 AV5In total, 40.9% had node-positive disease (N1-N2).Following neoadjuvant pembro plus chemotherapy, 44 (50.0%) of the included patients received adjuvant pembro monotherapy.pCR, defined as no residual invasive cancer in the breast or axillary lymph nodes (ypT0/Tis ypN0), was achieved by 61.4% of patients.Real-world event-free survival (rwEFS) was assessed, with 13 events observed among the included patients.When stratified by pathologic response, the estimated 3-year median rwEFS probability was 89.8% (95% confidence interval CI: 81.7-98.8%)among patients achieving pCR, versus 71.2% (95% CI: 55.9-90.7%)among those not achieving pCR.Conclusions: Neoadjuvant pembro plus chemotherapy was associated with high rates of pCR and favorable survival after three years.Patients achieving pCR showed improved event-free survival, highlighting the clinical relevance of pCR as a prognostic marker in managing patients with high-risk early-stage TNBC.These findings support the effectiveness of pembrolizumab-containing neoadjuvant therapy outside of clinical trial settings.

AI에게 질문

Bookmark

View Full Paper